Efficacy of switching from originator adalimumab to biosimilar adalimumab-AACF in patients with axial spondyloarthritis: a 12-month observational study

Efficacy of switching from originator adalimumab to biosimilar adalimumab-AACF in patients with axial spondyloarthritis: a 12-month observational study

Aim: The use of anti-TNF drugs is well-established for treating axial spondyloarthritis (axSpA). The introduction of biosimilars offers a more accessible alternative, but data on the switching of adalimumab biosimilars in the axSpA population remain somewhat controversial and are limited to SB5 and...

Full description

Saved in:
Bibliographic Details
Main Authors: Fanny Alcira Reyes Neira, Barbara Bayeh, Karina Rossi Bonfiglioli, Nadia Emi Aikawa, Ana Paula Luppino Assad, Renata Miossi, Fernando Henrique Carlos de Souza, Carlos Emilio Insfrán, Henrique Ayres Mayrink Giardini, Emily Figueiredo Vieira Neves Yuki, Eloisa Bonfa, Carla Gonçalves Schahin Saad, Ana Cristina de Medeiros-Ribeiro, Julio Cesar Bertacini de Moraes, Andrea Yukie Shimabuco
Format: Article
Language:English
Published: Open Exploration Publishing Inc. 2025-02-01
Series:Exploration of Musculoskeletal Diseases
Subjects:
anti-tnf biologics
biosimilar
originator
adalimumab
axial spondyloarthritis
Online Access:https://www.explorationpub.com/uploads/Article/A100783/100783.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items